2024 A Focus on Hematologic Malignancies


wednesday, sept. 11, 2024 | 1-5 p.m. ET
Live via Zoom Webinar

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for hematologic malignancies. FREE for healthcare professionals, students, patients and patient advocates.

New for 2024

  • Addresses the CAR T -associated secondary malignancies, how to identify and manage them, and the latest developments in the FDA investigation
  • Toxicities beyond CRS and ICANS, and a presentation on financial toxicities and access to therapy is also planned
The 2024 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.  (MSD), and Novartis Pharmaceuticals Corporation (supporters as of March 22, 2024).

Program Organizers

Natalie S. Callander, MD
University of Wisconsin-Madison

Matthew Frigault, MD, MSc
Massachusetts General Hospital

Nirav Shah, MD, MSHP
Medical College of Wisconsin

Program Snapshot

Credits Available
Physician Education: Credit being determined
Pharmacy Education: Credit being determined
Nursing Education: Credit being determined

Program Date & Location

Wednesday, Sept. 11, 2024 at 1-5 p.m. ET
Live via Zoom Webinar

Program Cost

FREE for healthcare professionals, students, patients and patient advocates.

Register for A Focus on Hematologic Malignancies >

Program Agenda

1-1:05 p.m.


Welcome and Introduction

1:05-1:30 p.m.


Lymphoma: Current State, Practical Considerations

Nirav Shah, MD, MSHP – Medical College of Wisconsin

1:30-1:55 p.m.


Leukemia: Current State, Practical Considerations

Lori Muffly, MD – Stanford University 

1:55-2:20 p.m.


Myeloma: Sequencing of Treatments, Options for Retreatment

Natalie Callander, MD – University of Wisconsin - Madison

2:20-2:45 p.m. 


Late Considerations After CAR T Therapy 

Jay Spiegel, MD University of Miami

2:45-3 p.m.



3-3:20 p.m.


Cancer Immunotherapy In Practice – Atypical Toxicities 

Matthew Frigault, MD, MSc – Massachusetts General Hospital

3:20-3:40 p.m.


Cancer Immunotherapy In Practice – ICANS, Neurological Effects

3:40-4 p.m.


Cancer Immunotherapy In Practice – Financial Toxicities

Rachel Cusatis, PhD Medical College of Wisconsin

4-5 p.m.


Faculty Case Study Panel

5 p.m.


Closing Remarks


This program is part of the SITC ACI series. View below to explore more programs in the 2024 ACI series.

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

Program Learning Objectives

  • Identify the cancer immunotherapy approaches in use for the treatment of hematologic malignancies for key disease states.
  • Summarize recent updates in cancer immunotherapy for hematologic malignancies including emerging toxicities and management.
  • Implement cancer immunotherapy for hematologic malignancies into clinical practice appropriately.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is approved for AMA PRA Category 1 Credits™, ABIM MOC credit, ANCC and ACPE contact hours.


Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Avoid Fraudulent ACI Registration Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.